Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

Hashimoto,Kentaro; Ozasa,Hiroaki; Yoshizawa,Akihiko; Yoshida,Hiroshi; Ogimoto,Tatsuya; Hosoya,Kazutaka; Yamazoe,Masatoshi; Ajimizu,Hitomi; Funazo,Tomoko; Yoshida,Hironori; Sakamori,Yuichi; Hirai,Toyohiro

doi:10.3892/ol.2022.13522

November-2022 Volume 24 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2022 Volume 24 Issue 5

Full Size Image

Case Report Open Access

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

Authors:
- Kentaro Hashimoto
- Hiroaki Ozasa
- Akihiko Yoshizawa
- Hiroshi Yoshida
- Tatsuya Ogimoto
- Kazutaka Hosoya
- Masatoshi Yamazoe
- Hitomi Ajimizu
- Tomoko Funazo
- Hironori Yoshida
- Yuichi Sakamori
- Toyohiro Hirai
View Affiliations / Copyright

Affiliations: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto‑shi, Kyoto 606‑8507, Japan, Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto‑shi, Kyoto 606‑8507, Japan

Copyright: © Hashimoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 402
|
Published online on: September 22, 2022

https://doi.org/10.3892/ol.2022.13522
Expand metrics +

Abstract

Immune checkpoint therapy (ICT) with nivolumab has been widely used to treat malignant pleural mesothelioma (MPM) since clinical trials confirmed its efficacy. However, only a few clinical trials have been conducted for the treatment of sarcomatoid MPM, which is a rare histological type of MPM. Additionally, clinical reports of sarcomatoid MPM are scarce. Therefore, the benefits and risks of nivolumab treatment for sarcomatoid MPM remain unclear. The present report describes the treatment of 3 cases of sarcomatoid MPM (all 3 were men) with nivolumab monotherapy. In all three cases, nivolumab was effective despite variations in the duration of treatment, although side effects were observed in 2 patients. Programmed death ligand 1 (PD‑L1) expression was positive in all 3 cases. In particular, the patient with the highest PD‑L1 expression had the most rapid response of the 3 patients, and the effect lasted as long as those of the other 2, despite receiving the smallest number of doses of nivolumab. It has been reported that sarcomatoid MPM tends to respond poorly to chemotherapy and express higher levels of PD‑L1 than epithelial MPM; thus, ICT may be necessary in these cases. This case series suggests that ICT with nivolumab is a promising treatment option for sarcomatoid MPM.

View Figures

View References

1	Schumann SO, Kocher G and Minervini F: Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 13:2510–2523. 2021. View Article : Google Scholar : PubMed/NCBI
2	Galateau-Salle F, Churg A, Roggli V and Travis WD; world health organization committee for tumors of the Pleura, : The 2015 world health Organization classification of tumors of the pleura: Advances since the 2004 classification. J Thorac Oncol. 11:142–154. 2016. View Article : Google Scholar : PubMed/NCBI
3	Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, et al: Clinical efficacy and safety of nivolumab: Results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural mesothelioma (MERIT). Clin Cancer Res. 25:5485–5492. 2019. View Article : Google Scholar : PubMed/NCBI
4	Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, et al: Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20:239–253. 2019. View Article : Google Scholar : PubMed/NCBI
5	Yamazoe M, Ozasa H and Kim YH: Effectiveness of nivolumab on sarcomatoid malignant pleural mesothelioma with eosinophilia and eosinophilic pleural effusion. J Thorac Oncol. 14:e251–e253. 2019. View Article : Google Scholar : PubMed/NCBI
6	Tsubouchi K, Inoue S, Ibusuki R, Iwasaki T and Harada T: Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1. Respirol Case Rep. 8:e005362020. View Article : Google Scholar : PubMed/NCBI
7	Mansfield AS, Symanowski JT and Peikert T: Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer. 86:133–136. 2014. View Article : Google Scholar : PubMed/NCBI
8	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
9	Nguyen BH, Montgomery R, Fadia M, Wang J and Ali S: PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. Asia Pac J Clin Oncol. 14:69–73. 2018. View Article : Google Scholar : PubMed/NCBI
10	Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, et al: Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: A series of 214 cases from the bio-MAPS cohort. Clin Lung Cancer. 20:e564–e575. 2019. View Article : Google Scholar : PubMed/NCBI
11	Zhang F and Gong W: Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis. Int Immunopharmacol. 83:1064812020. View Article : Google Scholar : PubMed/NCBI
12	Fujimoto N, Okada M, Kijima T, Aoe K, Kato T, Nakagawa K, Takeda Y, Hida T, Kanai K, Hirano J and Ohe Y: Clinical efficacy and safety of nivolumab in Japanese patients with malignant pleural mesothelioma: 3-year results of the MERIT study. JTO Clin Res Rep. 2:1001352021.PubMed/NCBI
13	Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim SW, Costa EC, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI
14	Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Related Articles